VIRIDIAN THERAPEUTICS INC. - COMMON STOCK

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

03 5 2022 08:00:02 提供 Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

06 4 2022 08:00:01 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

04 4 2022 16:05:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

21 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

14 3 2022 16:05:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

10 3 2022 16:05:01 提供 Nasdaq GlobeNewswire

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

03 3 2022 16:16:09 提供 Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

14 2 2022 08:00:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

31 1 2022 07:00:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

04 1 2022 07:00:02 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

20 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

15 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

04 11 2021 16:05:02 提供 Nasdaq GlobeNewswire

Viridian Therapeutics to Present at Upcoming Investor Conferences

03 11 2021 16:05:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

14 10 2021 08:00:01 提供 Nasdaq GlobeNewswire

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

30 9 2021 08:06:29 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

23 9 2021 16:01:00 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock

21 9 2021 00:22:28 提供 Nasdaq GlobeNewswire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

20 9 2021 16:01:00 提供 Nasdaq GlobeNewswire